Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Non-Current Assets (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Non-Current Assets readings, the most recent being $2.1 billion for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 5.76% to $2.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $8.4 billion, a 20.77% increase, with the full-year FY2025 number at $2.1 billion, up 5.76% from a year prior.
  • Non-Current Assets hit $2.1 billion in Q4 2025 for Neurocrine Biosciences, roughly flat from $2.1 billion in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $2.1 billion in Q2 2025 to a low of $761.0 million in Q1 2021.
  • Median Non-Current Assets over the past 5 years was $1.2 billion (2022), compared with a mean of $1.4 billion.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 192.62% in 2021 and later fell 17.7% in 2023.
  • Neurocrine Biosciences' Non-Current Assets stood at $1.1 billion in 2021, then fell by 16.78% to $915.2 million in 2022, then skyrocketed by 79.68% to $1.6 billion in 2023, then grew by 21.26% to $2.0 billion in 2024, then increased by 5.76% to $2.1 billion in 2025.
  • The last three reported values for Non-Current Assets were $2.1 billion (Q4 2025), $2.1 billion (Q3 2025), and $2.1 billion (Q2 2025) per Business Quant data.